

Listing of the Claims:

1-4. (Canceled)

5. (Currently Amended) An antisense oligonucleotide ~~consisting essentially comprising 10 or more contiguous bases of the~~ nucleotide sequence ~~A, C, D, E, F, G, H, I, J, K, L, or M~~ set forth in any one of [{}]SEQ ID NOS: 1 and 3-13~~, respectively~~ wherein the oligonucleotide is conjugated to a peptide and wherein the oligonucleotide is complementary to a bcl-xL-encoding mRNA and inhibits translation thereof.

6-8. (Canceled)

9. (Currently Amended) An antisense oligonucleotide consisting of the nucleotide sequence ~~B—(set forth in~~ SEQ ID NO:2[{}]] wherein the oligonucleotide is conjugated to a peptide and wherein the oligonucleotide is complementary to a bcl-xL-encoding mRNA and inhibits translation thereof.

10-42. (Canceled)

43. (Currently Amended) A ~~pharmaceutical~~ composition comprising an effective amount of an antisense oligonucleotide of claim 5 and a pharmaceutically acceptable carrier, wherein the effective amount is between 0.1 μ M and 10 μ M.

44-47. (Canceled).